These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
29. Overt diabetic neuropathy: repair of axo-glial dysjunction and axonal atrophy by aldose reductase inhibition and its correlation to improvement in nerve conduction velocity. Sima AA; Prashar A; Nathaniel V; Bril V; Werb MR; Greene DA Diabet Med; 1993 Mar; 10(2):115-21. PubMed ID: 8458187 [TBL] [Abstract][Full Text] [Related]
30. Characterization of a novel aldose reductase inhibitor, FR74366, and its effects on diabetic cataract and neuropathy in the rat. Ao S; Shingu Y; Kikuchi C; Takano Y; Nomura K; Fujiwara T; Ohkubo Y; Notsu Y; Yamaguchi I Metabolism; 1991 Jan; 40(1):77-87. PubMed ID: 1898618 [TBL] [Abstract][Full Text] [Related]
31. Aldose reductase inhibition by AS-3201 in sural nerve from patients with diabetic sensorimotor polyneuropathy. Bril V; Buchanan RA Diabetes Care; 2004 Oct; 27(10):2369-75. PubMed ID: 15451902 [TBL] [Abstract][Full Text] [Related]
32. Effects of long-term aldose reductase inhibition on development of experimental diabetic neuropathy. Ultrastructural and morphometric studies of sural nerve in streptozocin-induced diabetic rats. Yagihashi S; Kamijo M; Ido Y; Mirrlees DJ Diabetes; 1990 Jun; 39(6):690-6. PubMed ID: 2140802 [TBL] [Abstract][Full Text] [Related]
33. Increased levels of aldose reductase in peripheral mononuclear cells from type 2 diabetic patients with microangiopathy. Hasegawa G; Obayashi H; Kitamura A; Hashimoto M; Shigeta H; Nakamura N; Kondo M; Nishimura CY Diabetes Res Clin Pract; 1999 Aug; 45(1):9-14. PubMed ID: 10499880 [TBL] [Abstract][Full Text] [Related]
35. [Role of polyols in the development of diabetic complications. Value of aldose-reductase inhibitors]. Brogard JM; Caro-Sampara F; Blicklé JF Rev Med Interne; 1992; 13(1):69-79. PubMed ID: 1410879 [TBL] [Abstract][Full Text] [Related]
36. The pharmacology of aldose reductase inhibitors. Kador PF; Robison WG; Kinoshita JH Annu Rev Pharmacol Toxicol; 1985; 25():691-714. PubMed ID: 3923907 [No Abstract] [Full Text] [Related]
37. Clinical investigation of epalrestat, an aldose reductase inhibitor, on diabetic neuropathy in Japan: multicenter study. Diabetic Neuropathy Study Group in Japan. Hotta N; Sakamoto N; Shigeta Y; Kikkawa R; Goto Y J Diabetes Complications; 1996; 10(3):168-72. PubMed ID: 8807467 [TBL] [Abstract][Full Text] [Related]
38. Effects of epalrestat, an aldose reductase inhibitor, on diabetic peripheral neuropathy in patients with type 2 diabetes, in relation to suppression of N(ɛ)-carboxymethyl lysine. Kawai T; Takei I; Tokui M; Funae O; Miyamoto K; Tabata M; Hirata T; Saruta T; Shimada A; Itoh H J Diabetes Complications; 2010; 24(6):424-32. PubMed ID: 19716319 [TBL] [Abstract][Full Text] [Related]
39. Does aldose reductase have a role in the development of the ocular complications of diabetes? Lightman S Eye (Lond); 1993; 7 ( Pt 2)():238-41. PubMed ID: 7607342 [TBL] [Abstract][Full Text] [Related]
40. The level of erythrocyte aldose reductase: a risk factor for diabetic neuropathy? Ito T; Nishimura C; Takahashi Y; Saito T; Omori Y Diabetes Res Clin Pract; 1997 Jun; 36(3):161-7. PubMed ID: 9237782 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]